Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval.
Rekić D, Azarov I, Knöchel J, Sokolov V, Nilsson C, Wernevik L, Han D, Rydén-Bergsten T, Ebrahimi A, Dota C, Carlsson B. Rekić D, et al. Br J Clin Pharmacol. 2022 Nov;88(11):4839-4844. doi: 10.1111/bcp.15425. Epub 2022 Jun 10. Br J Clin Pharmacol. 2022. PMID: 35653229 Free article.
An oral antisense oligonucleotide for PCSK9 inhibition.
Gennemark P, Walter K, Clemmensen N, Rekić D, Nilsson CAM, Knöchel J, Hölttä M, Wernevik L, Rosengren B, Kakol-Palm D, Wang Y, Yu RZ, Geary RS, Riney SJ, Monia BP, Isaksson R, Jansson-Löfmark R, Rocha CSJ, Lindén D, Hurt-Camejo E, Crooke R, Tillman L, Rydén-Bergsten T, Carlsson B, Andersson U, Elebring M, Tivesten A, Davies N. Gennemark P, et al. Among authors: rekic d. Sci Transl Med. 2021 May 12;13(593):eabe9117. doi: 10.1126/scitranslmed.abe9117. Sci Transl Med. 2021. PMID: 33980578
A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II.
Knöchel J, Nilsson C, Carlsson B, Wernevik L, Hofherr A, Gennemark P, Jansson-Löfmark R, Isaksson R, Rydén-Bergsten T, Hamrén B, Rekić D. Knöchel J, et al. Among authors: rekic d. CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1569-1577. doi: 10.1002/psp4.12866. Epub 2022 Oct 1. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 36126230 Free PMC article. Clinical Trial.
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.
Någård M, Ah-See ML, Strauss J, Wise-Draper T, Safran HP, Nadeau L, Edenfield WJ, Lewis LD, Rekić D, Dota C, Ottesen LH, Li Y, Mugundu GM. Någård M, et al. Among authors: rekic d. Cancer Chemother Pharmacol. 2023 Aug;92(2):141-150. doi: 10.1007/s00280-023-04555-2. Epub 2023 Jun 27. Cancer Chemother Pharmacol. 2023. PMID: 37368100 Free PMC article.
27 results